Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline and JSC Binnopharm enter vaccine production alliance in Russia
GSK and JSC Binnopharm today announced an alliance to enable the local secondary manufacture of a number of GSK vaccines in Russia.
-
Human Genome Sciences and GlaxoSmithKline announce vote of FDA advisory committee to recommend approval of Benlysta® for systemic lupus erythematosus
GSK & HGS announced, FDA has voted 13 to 2 to recommend BENLYSTA for the treatment of autoantibody-positive patients with active SLE.
-
New study findings show no benefit of prescription omega-3 fatty acids in prevention of recurrent symptomatic atrial fibrillation in affected patients
Findings from study show treatment with high-dose prescription omega-3 fatty acids did not reduce the recurrence of symptomatic AF.
-
GlaxoSmithKline and Fiocruz extend innovative collaboration to research and develop new medicines for neglected tropical diseases
GSK and Fiocruz have today announced a unique collaboration to research and develop new and innovative medicines to treat diseases.
-
GlaxoSmithKline receives approval in Japan for two medicines: Revolade and Xyzal
GSK announced that it has received approval in Japan from the Ministry of Health, Labour and Welfare for Revolade (eltrombopag).
-
GSK and Amicus Therapeutics enter exclusive worldwide agreement to develop and commercialise Amigal™ for Fabry disease
GSK and Amicus today announced a definitive agreement to develop and commercialise AmigalTM (migalastat HCl),
-
GSK completes previously reported settlement with U.S. Department of Justice regarding former manufacturing plant
GSK announced that it has finalised an agreement with the U.S. Attorneys Office for the District of Massachusetts and DOJ.
-
GSK announces Q3 results for 2010
Q3 EPS before major restructuring of 28.2p
-
GSK outlines approach to delivering advances in the treatment of rare diseases
Creating an environment that fosters innovation, intuition and scientific acumen to deliver breakthrough thinking and new medicines
-
GSK, Fondazione Telethon and Fondazione San Raffaele to collaborate on gene therapy for rare diseases
GSK, Fondazione Telethon and Fondazione San Raffaele today announced a new strategic alliance to research and develop novel treatments.
-
GSK increases support for WHO strategy to improve children’s health with new 5-year commitment to expand donations of albendazole medicine
At the launch of the World Health Organizations (WHO) first report on Neglected Tropical Diseases today.
-
GSK takes minority stake in newly formed Convergence Pharmaceuticals
GSK announced that it has taken an 18% minority equity stake in Convergence Pharmaceuticals Limited.
-
GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine)
GSK has made the decision not to pursue further worldwide development of Herpes Simplex Vaccine.
-
GlaxoSmithKline receives EU approval for a new therapeutic indication for Arixtra® (fondaparinux)
GSK confirmed today that the European Commission has granted an amendment of their marketing authorisation for their anti-clotting agent.
-
GSK regulatory update on Avandia following EMA and FDA reviews
GSK confirms that following a review of Avandia® (rosiglitazone maleate) by the EMA and the FDA.
-
GSK EU regulatory update on Pandemrix™
GSK confirmed that on behalf of the EMA, CHMP has concluded that the available data are insufficient to Pandemrix and narcolepsy.
-
GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme
Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential developmental combination treatment
-
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
GSK and Genmab announced today plans to refocus the development programme of ofatumumab in autoimmune indications.
-
Three-year results from ECLIPSE study indicate that COPD patients may require prevention strategies to manage exacerbations, regardless of disease severity
Today the New England Journal of Medicine published results from ECLIPSE, an extensive research programme sponsored by GSK.
-
GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain
BJD international initiative and GSK today announced the launch of the LIBERATE™ joint pain management programme.